600436.SHG Zhangzhou Pientzehuang Pharmaceutical Co Ltd
- Market cap
- CNY 81.6B
- P/E
- 62.1x
- P/B
- 5.75x
- ROE
- 12.1%
- Dividend yield
- 2.41%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600436.SHG undervalued?
Graham numberThe Graham number of Zhangzhou Pientzehuang Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhangzhou Pientzehuang Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhangzhou Pientzehuang Pharmaceutical Co Ltd yet.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally. The company offers traditional Chinese medicines and health products in various forms, including capsule, ointment, tablet, syrup, and pill; health care food and functional drinks; special efficacy cosmetics; and household chemicals under the Pien Tze Huang brand name. It is also involved in the sale of food…
Full company profileZhangzhou Pientzehuang Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.31B | 3.71B | 4.77B | 5.72B | 6.51B | 8.02B | 8.69B | 10.1B | 10.8B | 9.00B | 8.47B |
| Gross Profit | 1.11B | 1.60B | 2.01B | 2.52B | 2.93B | 4.05B | 3.96B | 4.70B | 4.60B | 3.28B | 3.21B |
| Operating Income | 605M | 947M | 1.32B | 1.64B | 1.98B | 2.87B | 2.98B | 3.39B | 3.57B | 2.25B | 1.95B |
| EBITDA | 640M | 944M | 1.30B | 1.62B | 1.88B | 2.85B | 2.90B | 3.30B | 3.47B | 2.69B | 1.96B |
| Net Income | 536M | 807M | 1.14B | 1.37B | 1.67B | 2.43B | 2.47B | 2.80B | 2.98B | 2.16B | 1.72B |
| EPS | 0.89 | 1.34 | 1.89 | 2.28 | 2.77 | 4.03 | 4.10 | 4.64 | 4.93 | 3.58 | 2.85 |
| Balance Sheet | |||||||||||
| Total Assets | 5.04B | 5.65B | 6.66B | 8.81B | 10.2B | 12.5B | 14.6B | 17.1B | 17.5B | 17.6B | 17.7B |
| Total Liabilities | 1.29B | 1.22B | 1.35B | 1.84B | 1.95B | 2.36B | 2.78B | 3.16B | 2.70B | 2.47B | 3.05B |
| Shareholders' Equity | 3.49B | 4.14B | 5.02B | 6.63B | 7.86B | 9.71B | 11.3B | 13.4B | 14.3B | 14.5B | 14.2B |
| Cash & Short-term Investments | 1.71B | 2.12B | 2.79B | 4.26B | 5.17B | 7.11B | 2.50B | 10.2B | 5.01B | 1.26B | 2.23B |
| Total Debt | 651M | 467M | 600M | 697M | 718M | 885M | 1.11B | 1.13B | 1.11B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 395M | 677M | 612M | -879M | 1.47B | 462M | 6.87B | 2.21B | 1.31B | 77.0M | - |
| Capital Expenditure | 91.0M | 51.9M | 74.2M | 65.4M | 419M | 92.2M | 175M | 142M | 1.07B | 340M | 614M |
| Free Cash Flow | 304M | 625M | 538M | -945M | 1.05B | 370M | 6.70B | 2.06B | 245M | -263M | 2.48B |
| Ratios | |||||||||||
| ROE | 15.3% | 19.5% | 22.8% | 20.7% | 21.3% | 25.1% | 21.8% | 20.9% | 20.9% | 14.8% | 12.1% |
| ROA | 10.6% | 14.3% | 17.2% | 15.6% | 16.4% | 19.5% | 16.9% | 16.4% | 17.0% | 12.3% | 9.7% |
| Net Profit Margin | 23.2% | 21.7% | 24.0% | 24.0% | 25.7% | 30.3% | 28.4% | 27.8% | 27.6% | 24.0% | 20.3% |
| Debt to Equity | 0.19x | 0.11x | 0.12x | 0.11x | 0.09x | 0.09x | 0.10x | 0.08x | 0.08x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.41%
- Forward dividend
- 2.64 CNY
- Payout ratio
- 91.2%
- Ex-dividend date
- Oct 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.97B | 3.26 | 91.2% |
| 2024 | CNY 2.13B | 3.52 | 71.5% |
| 2023 | CNY 785M | 1.30 | 28.0% |
| 2022 | CNY 730M | 1.21 | 29.5% |
| 2021 | CNY 543M | 0.90 | 22.3% |
| 2020 | CNY 495M | 0.82 | 29.6% |
| 2019 | CNY 362M | 0.60 | 26.3% |
| 2018 | CNY 284M | 0.47 | 24.9% |
| 2017 | CNY 197M | 0.33 | 24.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on May 24, 2016.
Who owns Zhangzhou Pientzehuang Pharmaceutical Co Ltd
- Insiders 62.64%
- Institutions 3.24%
- Public & others 34.12%
- Shares outstanding 603M
- Free float 225M
Zhangzhou Pientzehuang Pharmaceutical Co Ltd company profile
- Company name
- Zhangzhou Pientzehuang Pharmaceutical Co Ltd
- Ticker
- 600436.SHG
- ISIN
- CNE000001F21
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 30, 2003
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,886
- Fiscal year end
- December
- Address
- No. 1, Amber Road, Zhangzhou, China, 363000
- Phone
- 86 40 0918 0819
- Website
- zzpzh.com
About Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally. The company offers traditional Chinese medicines and health products in various forms, including capsule, ointment, tablet, syrup, and pill; health care food and functional drinks; special efficacy cosmetics; and household chemicals under the Pien Tze Huang brand name. It is also involved in the sale of food; production of skin, hair, and oral care daily products; biotechnology and medical device research and development; sale of medical machinery; and online wholesale and retail. The company's products are used for liver diseases, cardiovascular and cerebrovascular, cancer, cold, dermatology, and other applications. It exports its products. The company was founded in 1956 and is based in Zhangzhou, China. Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. operates as a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd management
4- Mr. Jin Ming HuangGM & Director · born 1966
- Mr. Tengyun WeiChief Engineer & Supervisor · born 1972
- Mr. Yi Xiong ShiDeputy General Manager · born 1974
- Mr. Ze Xiu ZhangDeputy General Manager · born 1985